Moreover, in the case of therapies targeting, e.g., EGFR in NSCLC, TAM receptors are known to mediate bypass signalling, resulting in resistance to EGFR inhibitors such as erlotinib, gefitinib, and osimertinib [36,170,171,172]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.